MY202406A - Oxazole compound crystal - Google Patents

Oxazole compound crystal

Info

Publication number
MY202406A
MY202406A MYPI2020005118A MYPI2020005118A MY202406A MY 202406 A MY202406 A MY 202406A MY PI2020005118 A MYPI2020005118 A MY PI2020005118A MY PI2020005118 A MYPI2020005118 A MY PI2020005118A MY 202406 A MY202406 A MY 202406A
Authority
MY
Malaysia
Prior art keywords
oxazole compound
crystal
compound crystal
specific
peaks
Prior art date
Application number
MYPI2020005118A
Other languages
English (en)
Inventor
Naohiko Kanai
Takayuki Yasutomi
Ryosuke Hirota
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MY202406A publication Critical patent/MY202406A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2020005118A 2018-04-04 2019-04-03 Oxazole compound crystal MY202406A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072717 2018-04-04
PCT/JP2019/014730 WO2019194211A1 (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Publications (1)

Publication Number Publication Date
MY202406A true MY202406A (en) 2024-04-27

Family

ID=66223774

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020005118A MY202406A (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Country Status (26)

Country Link
US (4) US11414391B2 (https=)
EP (2) EP4400167A3 (https=)
JP (4) JP7326295B2 (https=)
KR (2) KR102764726B1 (https=)
CN (1) CN111902402A (https=)
AU (2) AU2019249562B2 (https=)
BR (1) BR112020019377A2 (https=)
CA (1) CA3095866A1 (https=)
DK (1) DK3774745T3 (https=)
EA (1) EA202092393A1 (https=)
ES (1) ES2982586T3 (https=)
FI (1) FI3774745T3 (https=)
HR (1) HRP20240858T1 (https=)
HU (1) HUE066793T2 (https=)
IL (2) IL277730B2 (https=)
LT (1) LT3774745T (https=)
MX (1) MX2020010435A (https=)
MY (1) MY202406A (https=)
PH (1) PH12020551605A1 (https=)
PL (1) PL3774745T3 (https=)
PT (1) PT3774745T (https=)
SG (1) SG11202009564TA (https=)
SI (1) SI3774745T1 (https=)
TW (2) TW202515853A (https=)
WO (1) WO2019194211A1 (https=)
ZA (1) ZA202006134B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092393A1 (ru) * 2018-04-04 2021-01-25 Оцука Фармасьютикал Ко., Лтд. Кристаллическое соединение оксазола
TW202400154A (zh) 2022-03-25 2024-01-01 日商大塚製藥股份有限公司 創傷治療用組合物
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
US20260076788A1 (en) * 2024-09-17 2026-03-19 Natalie DeVoir Orthodontic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637559B2 (en) * 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
CN109879828A (zh) * 2012-08-30 2019-06-14 大塚制药株式会社 制造噁唑化合物的方法
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
EA202092393A1 (ru) * 2018-04-04 2021-01-25 Оцука Фармасьютикал Ко., Лтд. Кристаллическое соединение оксазола

Also Published As

Publication number Publication date
IL277730B2 (en) 2025-02-01
BR112020019377A2 (pt) 2021-01-05
TW202515853A (zh) 2025-04-16
EP3774745B1 (en) 2024-05-29
TWI860993B (zh) 2024-11-11
EP4400167A3 (en) 2024-09-25
AU2024220015B2 (en) 2026-03-26
PH12020551605A1 (en) 2021-04-26
US20210147370A1 (en) 2021-05-20
PT3774745T (pt) 2024-06-25
US11414391B2 (en) 2022-08-16
US11840512B2 (en) 2023-12-12
AU2019249562A1 (en) 2020-10-22
KR102764726B1 (ko) 2025-02-11
JP2025128238A (ja) 2025-09-02
CA3095866A1 (en) 2019-10-10
JP2022037040A (ja) 2022-03-08
FI3774745T3 (fi) 2024-06-19
IL277730B1 (en) 2024-10-01
SG11202009564TA (en) 2020-10-29
JP7326295B2 (ja) 2023-08-15
JP2024001115A (ja) 2024-01-09
ES2982586T3 (es) 2024-10-16
US20250250243A1 (en) 2025-08-07
ZA202006134B (en) 2023-03-29
KR20250022254A (ko) 2025-02-14
PL3774745T3 (pl) 2024-08-19
IL315425A (en) 2024-11-01
JP2021517111A (ja) 2021-07-15
KR20200139736A (ko) 2020-12-14
EP3774745A1 (en) 2021-02-17
EP4400167A2 (en) 2024-07-17
US20240076275A1 (en) 2024-03-07
HRP20240858T1 (hr) 2024-10-11
CN111902402A (zh) 2020-11-06
LT3774745T (lt) 2024-07-10
SI3774745T1 (sl) 2024-08-30
MX2020010435A (es) 2020-10-28
WO2019194211A1 (en) 2019-10-10
TW202012380A (zh) 2020-04-01
DK3774745T3 (da) 2024-06-17
US20220411386A1 (en) 2022-12-29
AU2019249562B2 (en) 2024-06-27
AU2024220015A1 (en) 2024-10-17
IL277730A (en) 2020-11-30
HUE066793T2 (hu) 2024-09-28
EA202092393A1 (ru) 2021-01-25

Similar Documents

Publication Publication Date Title
PH12020551605A1 (en) Oxazole compound crystal
GEP20247703B (en) Microbiocidal derivatives
ZA202103388B (en) Microbiocidal thiazole derivatives
GEAP202215540A (en) Pcsk9 antagonist compounds
GEP201706692B (en) Biaryl amide compounds as kinase inhibitors
GEAP202215479A (en) Magl inhibitors
PH12019550224A1 (en) Antitumoral compounds
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
PH12021550124A1 (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
FI3977993T3 (fi) 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä
RU2016146119A (ru) Новый кристалл тетрациклического соединения
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
IN2014CN00689A (https=)
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
NZ743699A (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2021004386A (es) Compuestos novedosos.
PH12018501132A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
EA201892566A1 (ru) Кристаллический полиморф 15в-гидрокси-осатерона ацетата
MY202100A (en) Crystal
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
MX2020012747A (es) Compuestos de uracilo y su uso.
AR107441A1 (es) Forma cristalina de cobicistat
EA202192903A1 (ru) Кристаллическая форма ингибитора plk4